Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-GRASPALL 2016 eryaspase study in PEG-asparaginase-hypersensitive Ph-negative acute lymphoblastic leukemia
2016-004451-70Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eryaspase in acute lymphoblastic leukemia (ALL), sponsored by Aarhus University Hospital. Primary endpoint: Safety and tolerability. Started Apr 2017; status: completed.
02
Drugs
eryaspase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-004451-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004451-70.